Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2012 Jun;69(6):728-32.
doi: 10.1001/archneurol.2011.1728.

Myopathy associated with antibodies to signal recognition particle: disease progression and neurological outcome

Shigeaki Suzuki  1 , Yukiko K Hayashi, Masataka Kuwana, Rie Tsuburaya, Norihiro Suzuki, Ichizo Nishino
Affiliations
Multicenter Study

Myopathy associated with antibodies to signal recognition particle: disease progression and neurological outcome

Shigeaki Suzuki et al. Arch Neurol. 2012 Jun.

Abstract

Objective: To characterize the clinical course of myopathy associated with antibodies to signal recognition particle (SRP), or anti-SRP myopathy.

Design: Case series.

Setting: Keio University Hospitals and National Institute of Neuroscience, National Center of Neurology and Psychiatry, Tokyo, Japan.

Patients: We reviewed clinical features of 27 patients with anti-SRP myopathy and analyzed disease progression and neurological outcome.

Main outcome measures: Anti-SRP antibodies in serum were detected by RNA immunoprecipitation assay using extracts of K562 cells.

Results: Of the 27 patients, 5 (19%) showed chronic progressive muscle weakness as well as atrophy of limbs and trunk muscles from a younger age with more severe neurological outcomes compared with the other 22 patients(81%) with the subacute form.

Conclusion: A subset of patients with anti-SRP myopathy can show a chronic progressive form associated with severe clinical deficits.

PubMed Disclaimer

Publication types

MeSH terms